Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Apr 13;7(4):237–247. doi: 10.1016/0882-4010(89)90042-9

Recently described innate broad spectrum virus inhibitors☆

Samuel Baron 1, David Niesel 1, Indra P Singh 1, Louese McKerlie 1, Joyce Poast 1, Ashok Chopra 1, Guido Antonelli 2, Ferdinando Dianzani 2, Dorian H Coppenhaver 1,∗
PMCID: PMC7135662  PMID: 2695738

The content is available as a PDF (782.4 KB).

Footnotes

☆

This work was supported by grants from Cooper Biomedical, Inc. and the U.S. Army Medical Research and Development Command (Contract No. DAMD17-86-C-6119). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army.

References

  • 1.Baron S, McKerlie L. Broadly active inhibitor of viruses spontaneously produced by many cell types in culture. Infect Immun. 1981;32:449–453. doi: 10.1128/iai.32.2.449-453.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Coppenhaver DH, Baron JL, McKerlie ML, Sabados J, Baron S. Size and stability of naturally occurring virus inhibitor. Antimicrob Agents Chemother. 1984;25:646–649. doi: 10.1128/aac.25.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sullivan ML, Niesel DW, Coppenhaver DH, Sabados J, Baron S. Characterizations of an antiviral agent from primary murine fibroblast cultures: murine tissue culture CVI. J Biol Regul Homeost Agents I. 1987:126–132. [PubMed] [Google Scholar]
  • 4.Kumar S, Baron S. Non-interferon cellular products capable of virus inhibition. Tex Rep Biol Med. 1982;41:395–399. [PubMed] [Google Scholar]
  • 5.Baron S. Mechanism of recovery from viral infection. Adv Viral Res. 1963;10:39–64. doi: 10.1016/s0065-3527(08)60696-x. [DOI] [PubMed] [Google Scholar]
  • 6.Buckler CE, Baron S. Antiviral action of mouse Interferon in heterologous cells. J Bacteriol. 1966;91:231–235. doi: 10.1128/jb.91.1.231-235.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Baron S, McKerlie ML, Hughes TK, Blalock JE. A non-interferon, broadly active antiviral substance. In: Kahn A, Hill NO, Dorn GL, editors. Interferon properties and clinical uses. Leland Fides Foundation Press; 1980. pp. 463–476. [Google Scholar]
  • 8.Hughes TK, Blalock JE, McKerlie JL, Baron S. Cell-produced viral inhibitor: possible mechanism of action and chemical composition. Infect Immun. 1981;32:454–457. doi: 10.1128/iai.32.2.454-457.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kumar S, McKerlie ML, Albrecht TL, Goldman AS, Baron S. 5th edn. Vol. 177. 1984. A broadly active viral inhibitor in human and animal organ extracts and body fluids (41918) pp. 194–211. (Proc Soc Exp Biol Med). [DOI] [PubMed] [Google Scholar]
  • 10.Baron JL, Li JL, McKerlie ML, Shabot M, Coppenhaver DH. A new subtype of a natural viral inhibitor (CVI) that is stable in the gastrointestinal tract. Microbial Pathogenesis. 1986;1:241–247. doi: 10.1016/0882-4010(86)90048-3. [DOI] [PubMed] [Google Scholar]
  • 11.Tamm I, Horsfall FL. A microprotein from human urine which reacts with influenza, mumps, and Newcastle diseases viruses. J Exp Med. 1952;95:71–97. doi: 10.1084/jem.95.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Takemoto KK, Fabisch P. 5th edn. Vol. 16. 1964. Inhibition of herpes virus by natural and synthetic acid polysaccharides; pp. 140–144. (Proc Natl Acad Sci USA). [DOI] [PubMed] [Google Scholar]
  • 13.Michaels RH. Studies of antiviral factors in human milk and serum. J Immunol. 1965;94:262. [PubMed] [Google Scholar]
  • 14.Fieldsteel AH. Non-specific antiviral substances in human milk active against arbovirus and murine leukemia virus. Cancer Res. 1974;34:712–715. [PubMed] [Google Scholar]
  • 15.Falkler WA, Jr, Divan AR, Halstead SB. A lipid inhibitor of dengue virus in human colostrum and milk: with a note on the absence of anti-dengue secretory antibody. Arch Virol. 1975;47:3–10. doi: 10.1007/BF01315587. [DOI] [PubMed] [Google Scholar]
  • 16.Welsh RM, Jr, Jensen FC, Cooper NR, Oldstone MA. Inactivation and lysis of oncornaviruses by human serum. Virology. 1976;74:432–440. doi: 10.1016/0042-6822(76)90349-4. [DOI] [PubMed] [Google Scholar]
  • 17.Welsh JK, Skurrie IJ, May JY. Use of Semliki forest virus to identify lipid-mediated antiviral activity and anti-alphavirus immunoglobulin A in human milk. Infect Immun. 1978;19:395–401. doi: 10.1128/iai.19.2.395-401.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Issacs CE, Thormar H, Pessolano T. Membrane-disruptive effect of human milk: inactivation of enveloped viruses. J Infect Dis. 1986;154:966–971. doi: 10.1093/infdis/154.6.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Matthews THJ, Lawrence MK, Nair CD, Tyrrell DAJ. Antiviral activity in milk of possible clinical importance. Lancet. 1976;ii:1387–1389. doi: 10.1016/s0140-6736(76)91922-x. [DOI] [PubMed] [Google Scholar]
  • 20.Albrecht T, Zucca M, Dianzani F. Studio su un inibitore della replicazione del virus della varicell-zoster. Estrato da Giornale Italiano Di Chemioterapia. 1980;27-N-2:103–105. [PubMed] [Google Scholar]
  • 21.Antonelli G, Dianzani F, Coppenhaver DH, Baron S, Calandra P, Folchitto G. An influenza virus inhibitor that acts late in the replication cycle. Antimicrob Agents Chemother. 1986;29:49–51. doi: 10.1128/aac.29.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Krizanova O, Ratbova V. Serum inhibitors of myxoviruses. Curr Top Microbiol Immunol. 1969;47:125. doi: 10.1007/978-3-642-46160-6_6. (1969) [DOI] [PubMed] [Google Scholar]
  • 23.Karzon DT. Non-specific viral inactivating substance (VIS) in human and mammalian sera. J Immunol. 1956;76:454–463. [PubMed] [Google Scholar]
  • 24.Kitamura T, Tanaka Y, Sugane M. Studies on a heat-labile variola virus inhibitor in normal sera II. Further characterization of the inhibitor and its activity. Intervirology. 1973;1:288–296. doi: 10.1159/000148857. [DOI] [PubMed] [Google Scholar]
  • 25.Shortridge KF, Ho WKK. Human serum lipoproteins as inhibitors of haemagglutination for selected togaviruses. J Gen Virol. 1974;23:113–116. doi: 10.1099/0022-1317-23-1-113. [DOI] [PubMed] [Google Scholar]
  • 26.Gerna G, Cattaneo E, Credra PM, Revelo MG, Achilli G. 5th edn. Vol. 163. 1980. Human coronavirus OC-43 serum inhibitor and neutralizing antibody by a new plaque-reduction assay; pp. 360–366. (Proc Soc Exp Biol Med). [DOI] [PubMed] [Google Scholar]
  • 27.Suribaldi L, Seganti L, Orise N, Stasio A, Valenti P. Inhibiting activity of human serum low density lipoproteins toward Sendai virus. Microbiologica. 1979;2:121–128. [Google Scholar]
  • 28.Thiry L, Cogniaux-LeClerc J, Content J, Tack L. Factors which influence inactivation of vesicular stomatitis virus by fresh human serum. Virology. 1978;87:384–393. doi: 10.1016/0042-6822(78)90142-3. [DOI] [PubMed] [Google Scholar]
  • 29.Allen R, Finkelstein RA, Sulkin SE. Viral inhibitors in normal animal sera. Tex Rep Biol Med. 1958;16:391–421. [PubMed] [Google Scholar]
  • 30.Yilma T, Owens S, Adamo S. Preliminary characterizations of a serum viral inhibitor. Am J Vet Res. 1985;46:2360–2362. [PubMed] [Google Scholar]
  • 31.Baron S, Sabados J, McKerlie ML, Coppenhaver DH. Antiviral activity in urine is attributale to ammonium salts. J Biol Regul Homeost Agents. 1989;3:67–70. [PubMed] [Google Scholar]
  • 32.Marsh M, Helenius A. Adsorptive endocytosis of Semliki forest virus. J Mol Biol. 1980;142:439–454. doi: 10.1016/0022-2836(80)90281-8. [DOI] [PubMed] [Google Scholar]

Articles from Microbial Pathogenesis are provided here courtesy of Elsevier

RESOURCES